Literature DB >> 7091195

Duplication (5p13 leads to pter): prenatal diagnosis and review of the literature.

G S Khodr, G Cadena, K L Le, K S Kagan-Hallet.   

Abstract

We describe a patient with a reciprocal translocation t(5,13) and her three offspring. The chromosome anomaly was ascertained after the birth of her first child, who had the cri-du-chat syndrome. Amniocentesis demonstrated the presence of a dup(5p). The anomalies affecting that fetus are described and compared with the reported phenotypes of dup(5p). The extent of clinical findings in the reported cases depends on the length of the duplicated portion. The larger the duplication (p11 leads to pter), the more pronounced are the clinical signs. Physical signs are nearly absent when 5p14 leads to ter is involved. Also, translocations affecting chromosome 5 have an increased abnormal outcome when compared to D/D Robertsonian translocations. This is the first instance of antenatal diagnosis of trisomy 5p.

Entities:  

Mesh:

Year:  1982        PMID: 7091195     DOI: 10.1002/ajmg.1320120106

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  3 in total

1.  Complete trisomy 5p owing to de novo translocation t(5;22)(q11;p11) with isochromosome 5p associated with a familial pericentric inversion of chromosome 2, inv 2(p21q11).

Authors:  E Orye; Y Benoit; B van Mele
Journal:  J Med Genet       Date:  1983-10       Impact factor: 6.318

2.  Human glial cell line-derived neurotrophic factor (GDNF) maps to chromosome 5.

Authors:  N Bermingham; R Hillermann; F Gilmour; J E Martin; E M Fisher
Journal:  Hum Genet       Date:  1995-12       Impact factor: 4.132

3.  A novel unbalanced translocation between chromosomes 5p and 18q leading to dysmorphology and global developmental delay.

Authors:  Giavanna Verdi; Dong Li; Sarah H Elsea; Beverly Nelson; Elizabeth J Bhoj; Hakon Hakonarson; Katherine R Yearwood; Sharmila Upadhya; Sarah Gluschitz; Janice L Smith; Andrew K Sobering
Journal:  Mol Genet Genomic Med       Date:  2022-02-21       Impact factor: 2.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.